Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients

Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco

David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital

Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail kkhush@medicine.ucsf.edu

Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.

Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco

David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital

Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail kkhush@medicine.ucsf.edu

Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.

Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco

David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital

Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail kkhush@medicine.ucsf.edu

Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.